Stockreport

Endo Has A Huge Opportunity — And Allergan May Want A Piece Of It [Investor's Business Daily]

Evolus, Inc.  (EOLS) 
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
PDF Related news Endo Pharmaceuticals ( ENDP ) is closing in on a $400 million opportunity for treating cellulite in the U.S. — and that could prompt top dog Allergan ( AGN [Read more]